MRI apparent diffusion coefficient (ADC): A biomarker for prostate cancer after radiation therapy
Yıl: 2021 Cilt: 47 Sayı: 6 Sayfa Aralığı: 448 - 451 Metin Dili: İngilizce DOI: 10.5152/tud.2021.21274 İndeks Tarihi: 14-05-2022
MRI apparent diffusion coefficient (ADC): A biomarker for prostate cancer after radiation therapy
Öz: Prostate specific antigen (PSA) remains the most used test to assess the response after therapies including the radiation therapy (RT). Apparent diffusion coefficient (ADC) derived from the conventional diffusionweighted imaging (DWI), as a part of noncontrast or biparametric MRI (bpMRI) (T2-weighted and DWI), offers diagnostic accuracy and cancer detection rate equivalent to that of multiparametric MRI. Cellular changes induced by RT can be quali-qualitatively demonstrated as early as 3months after RT as an increase in the signal intensity of the tumor on the ADC map. ADC, in association with PSA, represents a potential biomarker imaging for evaluating treatment efficacy in PCa both during and shortly after RT.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
- 1. Siegel RL, Miller KD, Fuchs HE, Jemad A. Cancer statistics 2021. Cancer J Clin. 2021;71(1):7-33. [CrossRef]
- 2. Roach M 3rd. Commentary on a multi-institutional analysis of external beam radiotherapy for T1-T2 prostate cancer: “love the one you’re with” and “do the right thing”. Int J Radiat Oncol Biol Phys. 2003;57(4):907-909. [CrossRef]
- 3. Kuhl CK, Bruhn R, Kra¨mer N, Nebelung S, Heidenreich A, Schrading S. Abbreviated biparametric prostate MR imaging in men with elevated prostate-specific antigen. Radiology. 2017;285:493-505. [CrossRef]
- 4. Scialpi M, Prosperi E, D’Andrea A, et al. Biparametric versus multiparametric MRI with non-endorectal coil at 3T in the detection and localization of prostate cancer. Anticancer Res. 2017;37(3):1263-1271. [CrossRef]
- 5. Scialpi M, D’Andrea A, Martorana E, et al. Biparametric MRI of the prostate. Turkish J Urol. 2017;43(4):401-409. [Cross- Ref]
- 6. Jung JW, Kang HR, Kim MH, et al. Immediate hypersensitivity reaction to gadolinium-based MR contrast media. Radiology. 2012;264:414-422. [Database] [CrossRef]
- 7. McDonald RJ, McDonald JS, Kallmes DF, et al. Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology. 2015;275:772-782. [CrossRef]
- 8. Sener RN. Diffusion MRI: Apparent diffusion coefficient (ADC) values in the normal brain and a classification of brain disorders based on ADC values. Comput Med Imaging Graph. 2001;25(4):299-326. [CrossRef]
- 9. Kim TH, Kim CK, Park BK, et al. Relationship between Gleason score and apparent diffusion coefficients of diffusion weighted magnetic resonance imaging in prostate cancer patients. Can Urol Assoc J. 2016;10:11-12.
- 10. Bhargava P, Ravizzini G, Chapin BF, Kundra V. Imaging biochemical recurrence after prostatectomy: Where are we headed? AJR Am J Roentgenol. 2020;214(6):1248-1258. [Cross- Ref]
- 11. Verma S, Rajesh A, Morales H, et al. Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. AJR Am J Roentgenol. 2011 Feb;196(2):374-81. [CrossRef]
- 12. Wu X, Reinikainen P, Vanhanen A, et al. Correlation between apparent diffusion coefficient value on diffusion-weighted MR imaging and Gleason score in prostate cancer. Diagn Interv Imaging. 2017;98(1):63-71. [CrossRef]
- 13. Scialpi M, Martorana E, Scialpi P, et al. Round table: Arguments in supporting abbreviated or biparametric MRI of the prostate protocol. Abdom Radiol. 2020;45(12):3974-3981. [CrossRef]
- 14. Maurer MH, Heverhagen JT. Diffusion weighted imaging of the prostate-principles, application, and advances. Transl Androl Urol. 2017;6(3):490-498. [CrossRef]
- 15. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618-629. [Cross- Ref]
- 16. Aisa MC, Piscioli I, Di Blasi A, Scialpi M. PSA/biparametric MRI: An accurate potential diagnostic approach for detection and management of local recurrence after radical prostatectomy. Turkish J Urol. 2020;46(1):87-88. [CrossRef]
- 17. Takayama Y,Kishimoto R,Hanaoka S, et alADC value and diffusion tensor imaging of prostate cancer: Changes in carbon-ion radiotherapy. JMagn Reson Imaging. 2008;27(6):1331-1335. [CrossRef]
- 18. Song I, Kim CK, Park BK, Park W. Assessment of response to radiotherapy for prostate cancer: Value of diffusion-weighted MRI at 3 T. Am J Roentgenol. 2010;194(6):W477-W482. [CrossRef]
- 19. Park SY, Kim CK, Park BK, et al. Early changes in apparent diffusion coefficient from diffusion-weighted MR imaging during radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2012;83(2):749-755. [CrossRef]
- 20. Decker G, Murtz P, Gieseke J, et al Intensity-modulated radiotherapy of the prostate: Dynamic ADC monitoring by DWI at 3.0 T. Radiother Oncol. 2014;113(1):115-120. [CrossRef]
- 21. Wu X, Reinikaineni P, Kapaneni M, et al. Diffusion-weighted MRI provides a useful biomarker for evaluation of radiotherapy efficacy in patients with prostate cancer. Anticancer Res. 2017;37:5027-5032.
- 22. Morgan VA, Riches SF, Giles S, Dearnaley D, deSouza NM. Diffusion- weighted MRI for locally recurrent prostate cancer after external beam radiotherapy. AJR Am J Roentgenol. 2012;198(3):596-602. [CrossRef]
- 23. Munoz F, Fiorica F, Caravatta L, et al. Outcomes and toxicities of re-irradiation for prostate cancer: A systematic review on behalf of the re-irradiation working group of the Italian association of radiotherapy and clinical oncology (AIRO). Cancer Treat Rev. 2021;95:102176. [CrossRef]
| APA | Scialpi M, Martorana E, Scialpi P, D ANDREA A, Mancioli F, Mignogna M, BLASI A, TRIPPA F (2021). MRI apparent diffusion coefficient (ADC): A biomarker for prostate cancer after radiation therapy. , 448 - 451. 10.5152/tud.2021.21274 |
| Chicago | Scialpi Michele,Martorana Eugenio,Scialpi Pietro,D ANDREA Alfredo,Mancioli Francesco Antonio,Mignogna Marcello,BLASI Aldo Di,TRIPPA Fabio MRI apparent diffusion coefficient (ADC): A biomarker for prostate cancer after radiation therapy. (2021): 448 - 451. 10.5152/tud.2021.21274 |
| MLA | Scialpi Michele,Martorana Eugenio,Scialpi Pietro,D ANDREA Alfredo,Mancioli Francesco Antonio,Mignogna Marcello,BLASI Aldo Di,TRIPPA Fabio MRI apparent diffusion coefficient (ADC): A biomarker for prostate cancer after radiation therapy. , 2021, ss.448 - 451. 10.5152/tud.2021.21274 |
| AMA | Scialpi M,Martorana E,Scialpi P,D ANDREA A,Mancioli F,Mignogna M,BLASI A,TRIPPA F MRI apparent diffusion coefficient (ADC): A biomarker for prostate cancer after radiation therapy. . 2021; 448 - 451. 10.5152/tud.2021.21274 |
| Vancouver | Scialpi M,Martorana E,Scialpi P,D ANDREA A,Mancioli F,Mignogna M,BLASI A,TRIPPA F MRI apparent diffusion coefficient (ADC): A biomarker for prostate cancer after radiation therapy. . 2021; 448 - 451. 10.5152/tud.2021.21274 |
| IEEE | Scialpi M,Martorana E,Scialpi P,D ANDREA A,Mancioli F,Mignogna M,BLASI A,TRIPPA F "MRI apparent diffusion coefficient (ADC): A biomarker for prostate cancer after radiation therapy." , ss.448 - 451, 2021. 10.5152/tud.2021.21274 |
| ISNAD | Scialpi, Michele vd. "MRI apparent diffusion coefficient (ADC): A biomarker for prostate cancer after radiation therapy". (2021), 448-451. https://doi.org/10.5152/tud.2021.21274 |
| APA | Scialpi M, Martorana E, Scialpi P, D ANDREA A, Mancioli F, Mignogna M, BLASI A, TRIPPA F (2021). MRI apparent diffusion coefficient (ADC): A biomarker for prostate cancer after radiation therapy. Turkish Journal of Urology, 47(6), 448 - 451. 10.5152/tud.2021.21274 |
| Chicago | Scialpi Michele,Martorana Eugenio,Scialpi Pietro,D ANDREA Alfredo,Mancioli Francesco Antonio,Mignogna Marcello,BLASI Aldo Di,TRIPPA Fabio MRI apparent diffusion coefficient (ADC): A biomarker for prostate cancer after radiation therapy. Turkish Journal of Urology 47, no.6 (2021): 448 - 451. 10.5152/tud.2021.21274 |
| MLA | Scialpi Michele,Martorana Eugenio,Scialpi Pietro,D ANDREA Alfredo,Mancioli Francesco Antonio,Mignogna Marcello,BLASI Aldo Di,TRIPPA Fabio MRI apparent diffusion coefficient (ADC): A biomarker for prostate cancer after radiation therapy. Turkish Journal of Urology, vol.47, no.6, 2021, ss.448 - 451. 10.5152/tud.2021.21274 |
| AMA | Scialpi M,Martorana E,Scialpi P,D ANDREA A,Mancioli F,Mignogna M,BLASI A,TRIPPA F MRI apparent diffusion coefficient (ADC): A biomarker for prostate cancer after radiation therapy. Turkish Journal of Urology. 2021; 47(6): 448 - 451. 10.5152/tud.2021.21274 |
| Vancouver | Scialpi M,Martorana E,Scialpi P,D ANDREA A,Mancioli F,Mignogna M,BLASI A,TRIPPA F MRI apparent diffusion coefficient (ADC): A biomarker for prostate cancer after radiation therapy. Turkish Journal of Urology. 2021; 47(6): 448 - 451. 10.5152/tud.2021.21274 |
| IEEE | Scialpi M,Martorana E,Scialpi P,D ANDREA A,Mancioli F,Mignogna M,BLASI A,TRIPPA F "MRI apparent diffusion coefficient (ADC): A biomarker for prostate cancer after radiation therapy." Turkish Journal of Urology, 47, ss.448 - 451, 2021. 10.5152/tud.2021.21274 |
| ISNAD | Scialpi, Michele vd. "MRI apparent diffusion coefficient (ADC): A biomarker for prostate cancer after radiation therapy". Turkish Journal of Urology 47/6 (2021), 448-451. https://doi.org/10.5152/tud.2021.21274 |
